Evidence map›Paper›PMID 34956603›Full record

ArticleInterface focus2021

Our mutual fiends: cancer research in a time of COVID-19.

K Dabin

Open access · hybridAbstract read
In one paragraph

Article in Interface focus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

K DabinScience Museum, London, UK.ORCID 0000-0003-0372-4998
Science Museum · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of the COVID-19 pandemic on health services in the UK and around the world cannot be understated. Cancer care services, patient and cancer research communities have been particularly affected. Screening services, treatment and clinical trials have been halted. Research laboratories have been closed or repurposed to tackle the pandemic. Despite these profound setbacks, there are ways in which the pandemic is accelerating areas of cancer research. In the context of a new cancer research exhibition planned by the Science Museum Group,

Indexed as

cancercancer carecancer researchCOVID-19researchvaccination

Identifiers

PMID34956603
PMCPMC8504881
OpenAlexW3205585730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.